Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services (WST) delivers essential innovations in pharmaceutical packaging and injectable drug delivery systems. This page provides investors and industry professionals with timely updates on the company’s strategic developments, financial performance, and technological advancements.
Access authoritative reporting on WST’s earnings announcements, regulatory milestones, product launches, and global partnerships. Our curated news ensures you stay informed about critical developments in elastomer-based components, biologics containment, and self-injection device platforms.
Explore updates across key areas: quarterly financial results, manufacturing expansions, compliance achievements, and collaborations with healthcare leaders. Content is rigorously verified to support data-driven decisions while adhering to financial disclosure standards.
Bookmark this page for streamlined access to WST’s evolving role in advancing safe, efficient drug delivery solutions worldwide. Check regularly for unbiased insights into one of pharma packaging’s most innovative players.
West Pharmaceutical Services (NYSE: WST) announced key executive leadership changes. Bernard J. Birkett, Senior Vice President and Chief Financial Officer, has announced his intention to retire this year after serving since June 2018. The company has initiated a search for his successor, with Birkett remaining as CFO during the transition period.
Additionally, Shane Campbell has been appointed as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025. Campbell joins from Carlisle Companies Inc., where he served as Chief Commercial Officer of the Construction Materials business, bringing 20 years of experience from DuPont in various senior global leadership roles.
During his tenure, Birkett played a important role in helping West navigate through global pandemic challenges, destocking complexities, and the emergence of GLP-1s. In 2022, he served as Chief Financial and Operations Officer before transitioning back to focusing solely on CFO responsibilities in April 2024.
West Pharmaceutical Services (NYSE: WST) reported Q1 2025 financial results with net sales of $698.0 million, showing a 0.4% increase and 2.1% organic growth. The company's reported-diluted EPS was $1.23, down from $1.55 year-over-year, while adjusted-diluted EPS reached $1.45.
The company has raised its full-year 2025 guidance, with net sales now projected at $2.945-2.975 billion, up from previous $2.875-2.905 billion. The adjusted-diluted EPS guidance was increased to $6.15-6.35, incorporating estimated tariff costs of $20-25 million.
In Q1, Proprietary Products segment saw 0.6% growth to $563.0 million, while Contract-Manufactured Products declined 0.7% to $135.0 million. The company repurchased 550,281 shares for $133.5 million and declared a Q3 2025 dividend of $0.21 per share, payable August 6, 2025.
West Pharmaceutical Services (NYSE: WST) has announced its upcoming first-quarter 2025 financial results release and conference call schedule. The company will disclose its Q1 results before market opening on Thursday, April 24, 2025, followed by a conference call at 9:00 a.m. Eastern Time to discuss financial performance and business expectations.
Interested participants must pre-register for the conference call to receive dial-in details and a unique PIN for asking questions. The event will include a live webcast and slide presentation, accessible through the Investors section of West's website. A replay of both the conference call and webcast will be available on the company website for approximately 90 days following the event.
West Pharmaceutical Services (NYSE: WST), a leader in injectable drug administration solutions, has announced its participation in two upcoming investor conferences in March 2025:
- The Barclays 27th Annual Global Healthcare Conference on March 12, 2025, at 11:00 AM ET
- The KBCM Healthcare Forum on March 19, 2025, at 1:30 PM ET
Both presentations will be accessible via live audio webcast through the company's website investor section. Interested parties can access replays of the presentations for approximately 90 days following the events.
West Pharmaceutical Services (NYSE: WST) has announced its second-quarter 2025 dividend payment. The company's Board of Directors has approved a dividend of $0.21 per share, which will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. West Pharmaceutical Services is recognized as a global leader in innovative solutions for injectable drug administration.
West Pharmaceutical Services (NYSE: WST) reported Q4 2024 results with net sales of $748.8 million, up 2.3% year-over-year, and organic net sales growth of 3.3%. Q4 reported-diluted EPS was $1.78, down 2.7%, while adjusted-diluted EPS was $1.82, down 0.5%.
The Proprietary Products segment saw Q4 net sales increase to $613.9 million with 4.5% organic growth, while Contract-Manufactured Products segment declined 2.5% to $134.9 million. High-Value Products represented 74% of Proprietary segment sales.
For full-year 2024, total net sales declined 1.9% to $2.893 billion, with adjusted-diluted EPS of $6.75, down 16.5%. The company's 2025 guidance projects net sales of $2.875-2.905 billion with organic growth of 2-3%, and adjusted-diluted EPS of $6.00-6.20.
West Pharmaceutical Services (NYSE: WST) has announced its upcoming fourth-quarter and full-year 2024 financial results release, scheduled for Thursday, February 13, 2025, before market opening. The company will host a conference call at 9:00 a.m. Eastern Time to discuss the results and business expectations.
Interested participants can access the live webcast through the company's Investor Relations website. To participate in the Q&A session, advance registration is required, after which participants will receive dial-in details and a unique PIN. A slide presentation will be available in the Investors section on the day of the call. The webcast replay will be accessible for approximately 90 days following the event.
West Pharmaceutical Services (NYSE: WST) has declared its first-quarter 2025 dividend. The Board of Directors approved a dividend payment of $0.21 per share, which will be distributed on February 11, 2025. Shareholders who are on record as of February 7, 2025, will be eligible to receive this dividend payment.
West Pharmaceutical Services (NYSE: WST) has announced the launch of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format at Pharmapack in Paris. The product, featuring multiple configurations, supports advanced therapies, particularly in cell and gene therapy treatments.
The PLASCAP® closure is a metal-free polypropylene cap with an integrated stopper, designed as a one-step press-fit solution for vial closure. It comes in ready-to-use, validated formats compatible with 13mm and 20mm crown vials. The new 6x8 nested tub configuration supports West 10ml nested CZ vials and selected nested vials with a 20mm crown.
West Pharmaceutical Services (NYSE: WST), a leader in injectable drug administration solutions, has announced its participation in the upcoming CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference. The company will be represented by Cindy Reiss-Clark (Sr. VP and Chief Commercial Officer), Chad Winters (VP of Finance and Chief Accounting Officer), and John Sweeney (VP of Investor Relations).
The presentation is scheduled for January 14, 2025, at 10:15 a.m. ET. Investors and interested parties can access the live audio webcast through the Investors section of West Pharmaceutical's website at www.westpharma.com.
